deferoxamine has been researched along with Experimental Hepatoma in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFO) is an iron chelating agent and has been known to have an antiproliferative effect in various malignant cells including hepatocellular carcinoma and the effect seems to be related to depletion of iron." | 1.29 | The effect of deferoxamine on the preneoplastic lesions in the chemically induced hepatocarcinogenesis. ( Jung, WH; Park, C; Park, YN, 1994) |
| "Transferrin recycling was confirmed by the demonstration of a progressive increase in the cellular molar ratios of iron to transferrin and by chase experiments." | 1.27 | Transferrin iron interactions with cultured hepatocellular carcinoma cells (PLC/PRF/5). ( Baynes, R; Bothwell, T; Bukofzer, G; Friedman, B; Macfarlane, B; McNamara, L, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, AC | 1 |
| Ingram, HA | 1 |
| Raymond, KN | 1 |
| Baker, E | 1 |
| Autelli, R | 1 |
| Crepaldi, S | 1 |
| De Stefanis, D | 1 |
| Parola, M | 1 |
| Bonelli, G | 1 |
| Baccino, FM | 1 |
| Patel, KR | 1 |
| Li, MP | 1 |
| Schuh, JR | 1 |
| Baldeschwieler, JD | 1 |
| Lindnér, P | 1 |
| Naredi, P | 1 |
| Peterson, A | 1 |
| Hafström, L | 1 |
| Park, YN | 1 |
| Jung, WH | 1 |
| Park, C | 1 |
| Itoh, H | 1 |
| Shioda, T | 1 |
| Matsura, T | 1 |
| Koyama, S | 1 |
| Nakanishi, T | 1 |
| Kajiyama, G | 1 |
| Kawasaki, T | 1 |
| Wood, SM | 1 |
| Gleadle, JM | 1 |
| Pugh, CW | 2 |
| Hankinson, O | 1 |
| Ratcliffe, PJ | 2 |
| Salceda, S | 1 |
| Beck, I | 1 |
| Caro, J | 1 |
| O'Rourke, JF | 1 |
| Bartlett, SM | 1 |
| De Leo, ME | 1 |
| Landriscina, M | 1 |
| Palazzotti, B | 1 |
| Borrello, S | 1 |
| Galeotti, T | 1 |
| Woods, KE | 1 |
| Ellis, AL | 1 |
| Randolph, JK | 1 |
| Gewirtz, DA | 1 |
| Baynes, R | 1 |
| Friedman, B | 1 |
| McNamara, L | 1 |
| Bothwell, T | 1 |
| Bukofzer, G | 1 |
| Macfarlane, B | 1 |
| Rogers, J | 1 |
| Munro, H | 1 |
13 other studies available for deferoxamine and Experimental Hepatoma
| Article | Year |
|---|---|
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Topics: Animals; Deferiprone; Deferoxamine; Ferric Compounds; Hepatocytes; Iron; Iron Chelating Agents; Iron | 2003 |
Intracellular free iron and acidic pathways mediate TNF-induced death of rat hepatoma cells.
Topics: Acids; Animals; Antioxidants; Apoptosis; Caspase Inhibitors; Cathepsins; Cell Line, Tumor; Cyclohexi | 2005 |
The pharmacological efficacy of a rigid non-phospholipid liposome drug delivery system.
Topics: Animals; Cholesterol; Deferoxamine; Drug Stability; Liposomes; Liver Neoplasms, Experimental; Methot | 1984 |
Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth.
Topics: Adenocarcinoma; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Divisi | 1995 |
The effect of deferoxamine on the preneoplastic lesions in the chemically induced hepatocarcinogenesis.
Topics: Animals; Deferoxamine; Diethylnitrosamine; Liver Neoplasms, Experimental; Male; Precancerous Conditi | 1994 |
Iron ion induces mitochondrial DNA damage in HTC rat hepatoma cell culture--role of antioxidants in mitochondrial DNA protection from oxidative stresses.
Topics: Animals; Antioxidants; Cell Line; Cells, Cultured; Deferoxamine; DNA Damage; DNA, Mitochondrial; In | 1994 |
The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells.
Topics: Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Base Sequence; Cell Hypoxia; Cell Nucleus; | 1996 |
Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia.
Topics: Actins; Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Blotting, Northern; Cell Hypoxia; C | 1996 |
Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1.
Topics: Adenylate Kinase; Animals; Cell Hypoxia; Chelating Agents; Deferoxamine; DNA-Binding Proteins; Gene | 1996 |
Iron modulation of LPS-induced manganese superoxide dismutase gene expression in rat tissues.
Topics: Animals; Deferoxamine; Gene Expression Regulation, Enzymologic; Iron; Lipopolysaccharides; Liver; Li | 1997 |
Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.
Topics: Animals; Cell Division; Cell Membrane; Daunorubicin; Deferoxamine; DNA Damage; DNA, Neoplasm; Doxoru | 1989 |
Transferrin iron interactions with cultured hepatocellular carcinoma cells (PLC/PRF/5).
Topics: 2,2'-Dipyridyl; Animals; Deferoxamine; Dose-Response Relationship, Drug; Endocytosis; Humans; Iron; | 1988 |
Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells.
Topics: Animals; Cell Line; Dactinomycin; Deferoxamine; DNA; Ferritins; Heme; Iron; Liver Neoplasms, Experim | 1987 |